CD28 and neoplasm: To extend the anti-tumor efficacy a third generation CAR-T cell, comprising two costimulatory endodomains such as CD28-OX40 or CD28-4-1BB, with an improved activation signal, prolonged proliferation and enhanced effector function, has been developed [40].